Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

155
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
155
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

487
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
487
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

154
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
154
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

992
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
992
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

127
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
127

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Global Impact to Pharmacoequity: A Call to Action for Clinical Pharmacology.

Clinical pharmacology and therapeutics·2026
Same author

Brain Structure of South African Children Born to Mothers on Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy.

Journal of the Pediatric Infectious Diseases Society·2026
Same author

Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.

Clinical and translational science·2026
Same author

Advancing Pharmacometrics in Africa: Insights and Perspectives From the 2025 Pharmacometrics Africa Conference.

Clinical pharmacology and therapeutics·2026
Same author

Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion.

The Journal of antimicrobial chemotherapy·2026
Same author

Responding appropriately to safety signals in infants exposed to the 6-month BDLLfx/BDLCfz regimen in utero.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Correction to "Physicians' Perceptions of Prescribing in Pregnancy and Package Inserts: A Survey of General and Hub Hospitals in Japan".

Clinical and translational science·2026
Same journal

Development of Core Competencies in Clinical Data Science Graduate Education: A Follow-On Tutorial to From Clinical Data Management to Clinical Data Science: Time for a New Educational Model.

Clinical and translational science·2026
Same journal

Population Pharmacokinetic, Exposure-Response Efficacy and Safety Analyses of Favezelimab in Patients With Solid Tumors.

Clinical and translational science·2026
Same journal

Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies.

Clinical and translational science·2026
Same journal

Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study.

Clinical and translational science·2026
Same journal

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.

Clinical and translational science·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.7K

Advancing Pharmacoequity in Low- and Middle-Income Countries via Model Informed Drug Development.

Henry Enzama1, Francis Williams Ojara1,2, Ian S Haworth3

  • 1Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.

Clinical and Translational Science
|April 27, 2026
PubMed
Summary
This summary is machine-generated.

Model-informed drug development (MIDD) and pharmacokinetic modeling can improve medicine access in low- and middle-income countries. These tools strengthen regulatory review and optimize dosing for better health equity.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Related Experiment Videos

Last Updated: Apr 28, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.7K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Regulatory Science
  • Global Health Equity

Background:

  • Persistent inequities in access to safe and effective medicines in low- and middle-income countries (LMICs).
  • Challenges include limited regulatory capacity, inadequate financing, and insufficient local data.
  • Uneven technical readiness and resource gaps hinder the adoption of model-informed drug development (MIDD) by regulatory authorities.

Purpose of the Study:

  • To explore the potential of model-informed drug development (MIDD) and pharmacokinetic modeling to address medicine access challenges in LMICs.
  • To highlight how these tools can strengthen regulatory processes and optimize drug dosing.
  • To emphasize the role of these approaches in advancing pharmacoequity.

Main Methods:

  • Utilizing physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) modeling.
  • Aligning modeling approaches with global harmonization initiatives.
  • Leveraging modeling to support evidence-based regulatory decisions.

Main Results:

  • Pharmacokinetic modeling can enhance the rigor of regulatory review processes.
  • Optimized dosing strategies can be developed for specific populations.
  • MIDD tools can facilitate the approval and accessibility of context-appropriate therapies.

Conclusions:

  • Model-informed drug development (MIDD) and pharmacokinetic modeling offer significant potential to improve medicine access and advance pharmacoequity.
  • Strengthening regulatory capacity and addressing resource gaps are crucial for successful implementation.
  • These advanced tools, when integrated with global harmonization efforts, can ensure patients in LMICs receive timely access to necessary medications.